Skip To Main Content
Elen Kristine Höglander on Muck Rack

Elen Kristine Höglander

As seen in: Genome Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Elen Kristine

Contact Elen Kristine, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations

|
By Elen Kristine Höglander, Silje Nord, David C. Wedge, Ole Christian Lingjærde
| Genome Medicine Verified
Patient material and study design Material was collected from women with breast cancer included in a randomized phase II trial evaluating the efficacy and safety of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) in combination with neoadjuvant treatment regimens. The inclusion criteria were met by patients with large (> 2.5 cm) Her2-negative tumors, with no signs of metastatic disease, and without receiving prior treatment.
Open in Who Shared Issue with article?
See all 1 articles